The Securities and Exchange Commission filed civil complaints against two brothers on Tuesday, alleging that Andrew W. Jacobs and his brother Leslie J. Jacobs II traded on inside information about a tender offer made by French pharmaceutical company Sanofi (NASDAQ:SNY) to buy OTC health-care manufacturer Chattem in 2010.

In a press release, the SEC said that in December 2009, Andrew learned from his brother-in-law, a Chattem executive, that the buyout was in the works. The brother-in-law told Andrew to keep the information confidential, alleges the SEC, but Andrew called his brother Leslie  to tell him of the deal -- at which point Leslie allegedly bought 2,000 shares of Chattem before the share price could rise in response to the buyout. Leslie then allegedly sold these shares and pocketed a $49,457.21 profit.

The SEC is now suing the brothers based on those allegations and asking that they disgorge their profits, and pay interest on the illicit profits and penalties. The SEC also wants Andrew Jacobs banned from serving as an officer or director of any public company for a period of time, inasmuch as he was serving in such a capacity for an unnamed public company at the time he allegedly passed confidential information to his brother.


This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.